EU Approves Sepalna for Advanced Ovarian Cancer

The European Commission granted maintenance treatment approval for adults with advanced ovarian, fallopian tube or peritoneal cancer responding to first-line chemotherapy.

Updated on Nov. 17, 2026 in Cancer

EU Approves Sepalna for Advanced Ovarian Cancer

The European Commission approved Sepalna (senaparib) as maintenance treatment for adults with FIGO stage 3 and 4 epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer whose disease responded to first-line platinum-based chemotherapy. The decision, granted on 12 November 2026, applies across the European Union and follows a positive CHMP opinion in September 2026.

Why it matters

The approval extends a maintenance option to patients with advanced ovarian cancer in the EU, supported by the phase 3 FLAMES study. Pharmanovia, which holds exclusive regional commercialisation rights, is preparing to introduce the treatment across Europe.

The FLAMES phase 3 trial reported median progression-free survival of 38.7 months with senaparib compared with 13.6 months on placebo at a median follow-up of 48.5 months. Among 403 patients in the updated safety data, 5.6% stopped treatment due to adverse events, and the extraction does not report outcomes beyond progression-free survival.

The players

Pharmanovia

Pharmanovia is a pharmaceutical company holding exclusive regional commercialisation rights for senaparib across 66 countries.

IMPACT Therapeutics

IMPACT Therapeutics is a drug developer that developed senaparib and supported the phase 3 FLAMES study.

The details

Senaparib, developed by IMPACT Therapeutics, is indicated for adults whose advanced epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer responded completely or partially to first-line platinum-based chemotherapy. The FLAMES study enrolled patients with newly diagnosed advanced ovarian cancer regardless of BRCA mutation status.

Timeline

  1. September 2026: The CHMP issued a positive opinion on senaparib.

  2. 12 November 2026: The European Commission granted approval for Sepalna.

  3. 17 November 2026: Pharmanovia and IMPACT Therapeutics announced the authorisation.

Big Picture

The approval rests on the phase 3 FLAMES study, which reported progression-free survival gains for senaparib maintenance over placebo in advanced ovarian cancer. It moves those trial results into regulatory approval and commercial availability across the European Union.

Adults with advanced ovarian, fallopian tube or peritoneal cancer whose disease responded to first-line chemotherapy may gain access to a maintenance option once Sepalna is introduced across Europe. The extraction does not specify availability timelines or pricing in individual countries.

The takeaway

Maintenance therapy after first-line chemotherapy is a key focus in advanced ovarian cancer, and the FLAMES results add a new option for eligible patients. Readers tracking treatment access should watch for country-level rollout as Pharmanovia introduces the drug.

Further reading

For related coverage, see Cancer news on treatment approvals and trial results.

Source note: This article includes information reported by PharmaTimes.